Alpha-9 Oncology Announces Presentation of Data for its GRPR-Targeting Imaging Compound 68Ga-A9-6217 at the European Association of Nuclear Medicine (EANM) 2026 Annual Congress
Alpha-9 Oncology Doses First Patient in Phase 1 Clinical Trial Evaluating GRPR-Targeted Radiotherapeutics Across Multiple Solid Tumors
